Trials / Unknown
UnknownNCT04679428
Immunological Characteristics of COVID-19 Patients
Immunological Characteristics of COVID-19 Patients and Determination of Neutralizing Antibodies Against SARS-CoV-2 Virus
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 230 (estimated)
- Sponsor
- The University Clinic of Pulmonary and Allergic Diseases Golnik · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will look at the immunological characteristics of COVID-19 patients and determine neutralizing antibodies against SARS-CoV-2 virus.
Detailed description
The immunogram (quantitative TBNK immunophenotipisation) will be performed by flow cytometry, the antibody response will be determined by IVD ELISa. Clinical biochemical and immunochemical (ECLIA) tests (including IL-6) will be performed on Cobas analyzers. Hemogram with differential blood picture will be performed with a hematology analyzer Sysmex XN 3100, examination of blood smears with CellaVision system or. microscope. Coagulation tests will be performed on BCS XP analyzers. An in-house system for the analysis of SARS-CoV-2 virus fusion inhibitors on human cells will be used to detect the ability of antibodies from patients' serum to neutralize the virus and thus potential protection against re-infection. The system is quantitative, meaning that the titer of such antibodies could be determined, and thus the potential level of protection would be evaluated.
Conditions
Timeline
- Start date
- 2020-05-07
- Primary completion
- 2022-05-07
- Completion
- 2023-05-07
- First posted
- 2020-12-22
- Last updated
- 2020-12-22
Locations
1 site across 1 country: Slovenia
Source: ClinicalTrials.gov record NCT04679428. Inclusion in this directory is not an endorsement.